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Abstract
Background: Evidence is accumulating that cognitive remediation therapy (CRT) is an effective intervention for
patients with schizophrenia or schizoaffective disorder. To date there has been no randomised controlled trial (RCT)
cohort study of cognitive remediation within a forensic hospital. The goal of this study is to examine the effectiveness
of a trial of cognitive remediation for forensic mental health patients with schizophrenia or schizoaffective disorder.
Methods: An estimated sixty patients will be enrolled in the study. Participants will be randomised to one of two
conditions: CRT with treatment as usual (TAU), or TAU. CRT will consist of 42 individual sessions and 14 group sessions.
The primary outcome measure for this study is change in cognitive functioning using the MATRICS Consensus
Cognitive Battery (MCCB). Secondary outcomes include change in social and occupational functioning, disorganised
symptoms, negative symptoms, violence, participation in psychosocial treatment and recovery. In addition to these
effectiveness measures, we will examine patient satisfaction.
Discussion: Cognitive difficulties experienced by schizophrenia spectrum patients are associated with general
functioning, ability to benefit from psychosocial interventions and quality of life. Research into the treatment of
cognitive difficulties within a forensic setting is therefore an important priority. The results of the proposed study will
help answer the question whether cognitive remediation improves functional outcomes in forensic mental health
patients with schizophrenia or schizoaffective disorder. Forensic mental health patients are detained for the dual
purpose of receiving treatment and for public protection. There can be conflict between these two roles perhaps
causing forensic services to have an increased length of stay compared to general psychiatric admissions. Ultimately a
focus on emphasising cognition and general functioning over symptoms may decrease tension between the core
responsibilities of forensic mental health services.
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Background
Forensic Mental Health Services (FMHS) provide treat-
ment for a minority of people with mental illnesses such
as schizophrenia who come into contact with law en-
forcement agencies as a consequence of their mental dis-
order, or who cannot be safely managed within another
service and require specialised therapeutically safe and
secure care and treatment for a period of time [1, 2].
The offences carried out by mental health patients are
heterogeneous and range from public order offences to
homicide. It is possible to divert mentally ill patients
charged with less serious offences to general psychiatric
services especially when detention in prison would be
detrimental to their health [3]. Forensic patients are
often judged to have lacked mental capacity to form a
criminal intent at the time of the offence. These patients
are deemed to be not responsible or diminished in re-
sponsibility for what they have done due to deficits in
comprehension, reasoning, and judgment [4]. The ‘in-
sanity defence’ available in some jurisdictions is a special
example of a loss of capacity within the context of crim-
inal charges such as homicide or serious assault. Patients
facing criminal charges and who receive a verdict of not
guilty by reason of insanity are admitted to a forensic
hospital so that they can receive treatment and to ameli-
orate the risk of future violence [2]. Frequently the dual
role of providing treatment and public protection is co-
dified in law as is the case for the Republic of Ireland’s
Criminal Law (Insanity) Act (2006) section 11(2) [5]. In
these circumstances independent tribunals tasked with
reviewing patients’ detention are asked to consider the
welfare and safety of the person and also the public
interest (Criminal Law Insanity Act 2010). Forensic
mental health services therefore have the dual role of
treating and caring for the patient and representing their
interests, whilst simultaneously protecting the public
from further harm through involuntary detention and
risk management [6, 7].
Length of stay within Forensic Mental Health
Forensic mental health patents are typically hospitalised
for longer periods than their non-forensic counterparts
[7–12]. International comparisons of length of stay are
difficult to establish because they are hampered by dif-
ferences in patient groups and criminal law [7] For the
Republic of Ireland the vast majority of forensic mental
health patients have a diagnosis of schizophrenia or schi-
zoaffective disorder with a small minority having bipolar
or depressive disorder. A diagnosis of personality dis-
order would not ordinarily meet the criteria of mental
disorder under Irish law and would thus not qualify to
receive compulsory mental health care in either the civil
or forensic services (Mental Health Act 2001 and Crim-
inal Law (Insanity) Act 2006). Even when acknowledging
differences in patient populations it would not be un-
usual for patients to be detained within a European con-
text for periods greater than five years [12] It is likely
that the dual role played by forensic mental health ser-
vices regarding the needs of the patient on the one hand
and society on the other is a contributing factor to
lengthy admissions [6].
Limitations of pharmacotherapy for treating schizophrenia
The primary treatment strategy for patients with schizo-
phrenia or schizoaffective disorder is pharmacotherapy
using antipsychotic medication, a proven and efficacious
intervention for the positive symptoms of schizophrenia
i.e. delusions and hallucinations [13]. Following initial
gains however, pharmacotherapy has limited efficacy for
improving patient functioning. Antipsychotics are not ef-
fective for treating the neurocognitive deficits associated
with schizophrenia such as problems with attention,
memory and executive functioning; nor do they have ef-
ficacy for treating stable, trait-like social cognitive defi-
cits such as emotional perception, theory of mind,
context sensitive processing, or emotional reasoning
[14]. Antipsychotics have also limited efficacy for treat-
ing negative symptoms such as avolition, anhedonia, ap-
athy, blunted affect, asociality, and alogia [15, 16]. It is
the neurocognitive impairment, social cognitive impair-
ment, and negative symptoms experienced by patients
with schizophrenia that are the strongest contributors to
functional outcome [17–20]. Meta-analyses consistently
demonstrate that both neurocognitive and social cogni-
tive deficits in addition to negative symptoms account
for more of the variance of suboptimal functioning than
positive symptoms [17–26]. Specifically neurocognitive
and social cognitive difficulties affect the ability to live
independently, to engage in meaningful work and to
benefit from psychosocial treatment programs. Ultim-
ately these impairments impact on patients’ quality of
life [27, 28]. Also negative symptoms are probably par-
tially attributable to cognitive impairments [29]. Because
of the centrality of neurocognitive problems for patient
functioning and because neurocognitive and social cog-
nitive deficits occur prior to the onset of psychotic
symptoms it has been argued that schizophrenia should
be reconceptualised as a cognitive rather than a psych-
otic disorder [27]. Moreover it has been suggested that
the development of new therapies for improving func-
tional outcomes for patients with schizophrenia has been
impeded by emphasising the psychotic features of the
disorder [27].
Limitations of psychological and occupational interventions
within forensic mental health
To address patients’ suboptimal functioning and violence
risk factors, forensic mental health services use an
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eclectic mix of occupational therapy and psychosocial
treatment programmes. Many of these interventions
have a limited evidence base within forensic mental
health practice [30–35]. But some specific programmes
such as ‘reasoning and rehabilitation’ have been formally
assessed, using violent behaviour and attitudes as out-
come measures [36, 37]. Also concern has been
expressed that patients with schizophrenia and other
psychotic disorders may not be able to benefit from such
programmes due to their negative symptoms and cogni-
tive deficits [19, 28]. Recently we found that a nationally
representative cohort of forensic mental health patients
with schizophrenia and schizoaffective disorder scored
more than three standard deviations below the popula-
tion mean on the MATRICS Consensus Battery for cog-
nitive deficits in schizophrenia [38]. Amongst patients
with schizophrenia difficulties can occur at any point of
the informational processing stream [39, 40]. Therefore
forensic mental health patients with schizophrenia may
not possess the necessary motivation and basic cognitive
abilities to attend to the information being presented,
store the information within their memory and utilise
the information when presented with future problems
and challenges. But because psychological interventions
have a robust evidence base for a variety of mental disor-
ders [41], it is probable that patients with schizophrenia
could benefit from such interventions if their cognitive
abilities could be partially remediated, or if their self-
efficacy and intrinsic motivation were enhanced.
Cognitive remediation therapy
One approach that has shown potential to improve pa-
tients’ cognitive and motivational difficulties in non-
forensic settings is cognitive remediation therapy [42–44].
Cognitive remediation therapy is a behaviourally based
training approach designed to help patients improve their
cognitive abilities and real world functioning. A variety of
therapies exist under the cognitive remediation umbrella
but most aim to either strengthen patients basic cognitive
capacities through a process of drill and practice, or to
teach patients more effective ways to deploy cognitive re-
sources using meta-cognitive strategies. Cognitive remedi-
ation is a nonthreatening activity which patients enjoy and
focuses on success and mastery experiences and therefore
has the potential to increase self-efficacy [45]. A recent
meta-analysis by Wykes has demonstrated that cognitive
remediation is an effective intervention for patients with
schizophrenia [42]. Within the Wykes meta-analysis, the
average patient with schizophrenia or schizoaffective dis-
order who received cognitive remediation improved per-
formance on cognitive tasks by an effect size of about .5
(Cohens d) and .42 on patient functioning. Also cognitive
remediation therapy has been shown to produce durable
improvements in cognition and functioning [42]. And
there is evidence that cognitive remediation can optimise
patients’ responses to psychosocial rehabilitation [46].
But the evidence base for cognitive remediation within
a forensic mental health setting is limited. To date only
two randomised trials have been conducted. One study
investigated the feasibility of improving social cognition
amongst forensic mental health patients [47]. The sec-
ond study mixed forensic mental health patients with
general mental health patients. Mixing general mental
health patients with forensic patients may undermine
the confidence with which the findings can be general-
ised to forensic mental health patients as a whole [48].
Of note within this study the forensic mental health pa-
tients were significantly more cognitively impaired on
working memory and verbal learning than the general
mental health patients. However both studies produced
positive outcomes on a range of measures including
recognising emotion, neurocognition, aspects of patient
functioning and patient satisfaction. Cognitive remedi-
ation therefore may be a promising intervention for foren-
sic mental health patients. In theory cognitive remediation
approaches have the potential not only to improve patients’
cognitive abilities and day to day functioning, but also con-
tribute to patients’ ability to benefit from additional psy-
chosocial and violence risk reduction programmes, thereby
enhancing recovery and perhaps reducing length of stay.
Functional capacity and public protection
The separation between patient care and treatment, and
public protection may be a false dichotomy. Although
the link between violence and schizophrenia is typically
attributed to psychotic symptoms such as delusions and
hallucinations, many violence risk factors within this
population concern suboptimal functioning [49–51]. Vio-
lence risk prediction or violence proneness schemes take
advantage of this and place the same weight on items con-
cerning suboptimal functioning as on items concerning
psychotic symptoms or other risk factors [51]. Homeless-
ness, employment problems, relationship difficulties, sub-
stance misuse, stress etc. are all risk factors for violence
[50]. Many of the violence risk factors associated with sub-
optimal functioning are probably related to the cognitive
difficulties experienced by patients with schizophrenia. It
may also be that forensic patients are more functionally
impaired than their non-forensic counterparts thus in-
creasing their violence proneness and creating the circum-
stances for them to come into contact with law
enforcement agencies [38]. Using a prospective cohort de-
sign, we have recently demonstrated that deficits in neuro-
cognition and social cognition accounted for a large
portion of the variance of reactive violence carried out by
forensic hospital patients with schizophrenia [38]. We also
found that neurocognitive deficits act as a distal risk factor
whose effects on reactive violence were mediated by more
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proximal factors such as problems with social reasoning,
impaired functioning, symptoms and violence proneness
[38].
Prioritising patient functioning over symptoms
Improving and where possible restoring patient func-
tioning is central to psychiatric care. But services may be
prone to emphasising the medical treatment of symp-
toms over interventions designed to restore patient func-
tioning. For instance, a recent investigation by the
Schizophrenia Commission into the provision of care for
people with psychosis in England found inpatient set-
tings to be “anti-therapeutic” with medication being
prioritised over psychological interventions [52]. Con-
cerning community care and treatment, one retrospect-
ive longitudinal study examining 25,000 Swedish
patients with schizophrenia found an increase in the rate
of adverse outcomes from 1972 to 2009. Amongst this
cohort there was an increase in premature death, violent
crime, and suicide [53]. The increase in the number of
adverse outcomes was notably associated with a decrease
in the numbers of inpatient beds and an increase of pa-
tients living in the community [53]. This finding may be
explained by pressure to discharge patients who do not
possess the necessary functional capacity to cope in the
community, but have received antipsychotic medication.
Clearly patients with low levels of functioning need high
levels of support delivered in either an appropriately
resourced community or hospital setting. But by placing
greater emphasis on treating and managing the cognitive
difficulties that underpin functional impairments, it may
also be possible to reduce violence and other adverse
outcomes. Although forensic mental health services have
a dual responsibility to provide care, in addition to man-
aging and decreasing violence risk, these are not neces-
sarily conflicting roles. The prioritisation of cognition
and function over symptoms may resolve the conflict be-
tween treatment and public protection. Any conflict that
does occur between care and public protection is more
likely to be a by-product of the limitations of particular
treatment approaches and conceptual paradigms. Be-
cause a focus on the cognitive and functional deficits ex-
perienced by forensic mental health patients has the
potential to bring the twin goals of patient care and public
protection into alignment, evaluating the effectiveness of
cognitive remediation is an important research priority.
Current study
To date there has been no randomised controlled cohort
study evaluating cognitive remediation therapy within a
forensic hospital although there have been feasibility and
mixed studies [47, 48]. Therefore an important objective
is to conduct a trial of cognitive remediation therapy
examining the effectiveness, functional outcomes and
patient satisfaction for a nationally representative cohort
of forensic mental health patients. We do not know
whether cognitive remediation is an effective rehabilita-
tion approach within this setting for improving cogni-
tion, reducing negative symptoms and improving general
functioning. Equally it is not clear whether cognitive re-
mediation has the ability to synergistically combine with
routine psychosocial and violence risk management pro-
grams and to enhance patients’ ability to benefit from
these interventions. Finally, it is not clear whether foren-
sic mental health patients would find it acceptable to
participate in an intensive programme of cognitive
remediation.
Hypotheses
The current study will aim 1) to test the efficacy of cog-
nitive remediation therapy for improving patient cogni-
tion, symptoms and functioning, where functioning
includes measures of participation in psychosocial treat-
ment programmes, recovery, and dynamic violence risk;
2) to establish patient satisfaction with cognitive remedi-
ation therapy within a forensic setting.
Method
The method was informed by the Clinical Trials As-
sessment Measure for psychological treatments, which
is an instrument designed to assess the quality of psy-
chological trials [54]. The Clinical Trials Assessment
Measure covers the domains of sample characteristics;
allocation to treatment (including allocation conceal-
ment, blinding, and randomisation); comparison treat-
ments; outcome assessment (including standardised
outcomes and blinding of participants); treatment de-
scription (including protocol and fidelity assessment);
and appropriate analysis (such as intention-to-treat
analysis). The validity measures for adherence to the
protocol will include rate of enrolment, rate of reten-
tion, tests of the success of blinding, and the number of
patients who complete the primary outcome measures.
This is a single centre randomised controlled trial.
Ethics, consent and permissions
The study was approved by the Research, Ethics and Audit
Committee of the National Forensic Mental Health
Service (NFMHS) and the School of Medicine Ethics
Committee, Trinity College Dublin. All patients participat-
ing in the study will provide informed signed consent.
Setting
The NFMHS provides specialised care for adults who
have a mental disorder and are at risk of harming them-
selves or others. At the time of the study the NFMHS
had 94 secure inpatient beds located on a single campus
(The Central Mental Hospital, CMH), and 13
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community beds. The CMH is the only secure forensic
psychiatric hospital for the Republic of Ireland, a popula-
tion of 4.6 million.
Participants
Approximately sixty patients under the care of the Central
Mental Hospital will be recruited to participate in this
study. Inclusion criteria are having a diagnosis of schizo-
phrenia or schizoaffective disorder established using the
Structured Clinical Interview for the Diagnostic and Statis-
tical Manual IV (SCID) [55] and being proficient in English.
Exclusion criteria are being acutely psychotic, being judged
too dangerous to participate in treatment (positive symp-
toms combined with aggressive or self-harming behaviour
in the last month) or being over 65 years of age. Inclusion
criteria are broad and exclusion criteria are minimal be-
cause we are primarily interested in investigating whether
CRT will be effective for a nationally representative cohort
of forensic mental health patients.
Randomisation and treatment allocation
Upon enrolment in the study participants will be rando-
mised to cognitive remediation and a waiting list control
group receiving treatment as usual (TAU) by the clinical
director of the Central Mental Hospital using ‘select
cases’ ‘random samples’ (select cases random number
generator) function in SPSS V21 [56]. Fig. 1 is a CON-
SORT diagram outlining patient allocation. Patients
randomised to receiving TAU will be offered the inter-
vention upon completion of the study. The clinicians
conducting the therapy sessions will be different from
the research team carrying out the assessments. The se-
quence of randomisation will be concealed from the re-
search team carrying out the baseline and outcome
assessments i.e. blinded assessment. All participants will
be trained not to reveal their study condition prior to
each follow up assessment. Should the blind be broken
this will be noted. Furthermore all assessors will be
asked to guess whether participants were receiving TAU
or CRT for each of the follow up assessments to see if
they perform at a chance level of accuracy. Patient par-
ticipation in CRT will be shared with their treating
psychiatrist. The socio-demographic characteristics of
the cognitive remediation group and the waiting list con-
trol group will then be compared on a range of measures
e.g. age, sex, dose of antipsychotic medication (expressed
as chlorpromazine equivalents) [57–59], pre-morbid IQ
(estimated from TOPFuk) [60], MATRICS global com-
posite scores, MATRICS domain scores, Social Cognitive
Scores [60–62], real world functioning (SOFAS), psychi-
atric symptoms (PANSS), negative symptoms (CAINS)
and violence proneness (HCR-20) [63–66].
Cognitive remediation therapy
Cognitive remediation therapy is a behaviourally based
training programme designed to improve cognitive prob-
lems associated with schizophrenia and schizoaffective
disorder [42–44]. Patients allocated to cognitive remedi-
ation will receive three individual sessions a week and
one group session for approximately 14 weeks, 56 ses-
sions in total.
The focus of the individual sessions is to enhance pa-
tients’ basic cognitive abilities through drill and practice
and to introduce patients to a variety of meta-cognitive
strategies to compensate for reduced performance ac-
cording to need [44]. Meta-cognitive strategies may be
distinct for particular cognitive domains e.g. the strat-
egies of problem identification, breaking problems into
parts, brainstorming, sequencing, monitoring, reflecting
may be particularly useful for problem solving. Whereas
strategies such as visualisation, chunking, association, re-
hearsal etc. may be helpful to compensate for memory
difficulties. And strategies like self-verbalisation may be
useful to enhance attentional abilities.
The focus of the group sessions is to help patients nor-
malise and develop insight into their cognitive difficul-
ties, to receive support and encouragement, and to
generalise gains [67]. A detailed manual has been devel-
oped to guide the delivery of the CRT support group.
Cognitive remediation operationalised by nine treatment
principles
Our cognitive remediation therapy is a principle driven
intervention consisting of nine treatment principles
(Table 1) and is in keeping with the recommendations of
a task force on Principles of Therapeutic Change that
Work, sponsored by the American Psychological Associ-
ation and the North American Society for Psychotherapy
Research [68]. In addition to the CRT literature the
approach is also influenced by the success of multi-
systemic therapy (MST), an empirically supported treat-
ment for conduct disorder. Multi-systemic therapy is a
flexible intervention operationalised by treatment princi-
ples rather than a prescriptive session format [69]. Con-
duct disorder, like schizophrenia is a heterogeneous
disorder and also has a history of being considered re-
fractory to psychological interventions. In contrast to
manualised protocols, principle driven interventions like
MST aim to provide clinicians with flexible heuristics ra-
ther than a set of tightly defined procedures prescribed
at specific times in therapy. The emphasis on broad
treatment principles rather than a scripted session for-
mat is therefore to facilitate a patient centred approach,
which is responsive to each patient’s own unique
strengths and vulnerabilities.
Our cognitive remediation programme also aims to
align the goals of forensic mental health services with
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the goals of individual patients. For example, forensic
mental health services may have a number of goals for
their patients concerning physical health, mental health,
substance misuse, harmful behaviour and occupational and
recreational functioning [70]. These goals may vary in their
level of explicitness, consist in a number of sub-goals, and
vary in the extent to which they are communicated to pa-
tients. Also in some cases the patients may not share the
service's goals but rather be a passive participant in the re-
habilitative process. For instance, they may not agree that
they have a substance misuse problem, have a mental ill-
ness or be at a high risk of violence. In these cases, the ser-
vice, psychiatrist, key-worker, multidisciplinary team and
other parties are the customers of the intervention and not
the patient. In contrast the starting point of our cognitive
remediation intervention is to help patients to clearly and
explicitly articulate their goals. Explicit links are then
drawn between cognitive difficulties and patient aspirations
and cognitive remediation is then offered as a vehicle
which can help actualise goals. Every attempt is made to fa-
cilitate the patient to take on the role of the customer. We
agree with Lindqvist and Skipworth who argue that it is
the hopes of the patient which are decisive for recovery
[33, 34].
Like MST our nine treatment principles are general state-
ments that can be easily remembered and applied, which
Fig. 1 Study outline. Following obtaining of ethical consent, participants were assessed and then randomised into the treatment as usual (TAU)
or cognitive remediation (CRT) and TAU interventions
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identify relational conditions, therapist behaviours, and
classes of interventions likely to lead to change. The treat-
ment principles attempt to integrate the specific theories
and techniques advocated by the CRT literature e.g. self-
verbalisation or monitoring, errorless learning, scaffolding
etc. combined with research into what makes psychological
interventions effective in general e.g. emphasising the thera-
peutic relationship, offering a credible rational for treat-
ment, and routinely evaluating progress [41, 71].
Wykes defines self-monitoring, errorless learning and
scaffolding as follows [43]. Self-monitoring is a technique
for rehearsal of both the task instructions as well as task
completion and can be accomplished by using verbalisa-
tion either overtly or covertly. Errorless learning is a tech-
nique whereby the therapist minimises opportunities for
the participant to make errors. For example, individuals
only attempt tasks where they have an 80 % success rate.
Finally scaffolding is a technique whereby the therapist
challenges the participant to complete difficult tasks but
with the assistance and guidance of the therapist. Our
nine treatment principles are also in keeping with recent
developments within the CRT literature, where it is has
been found that the therapeutic relationship, emotional
state, and the motivation of participants, in addition to an
emphasis on skills transfer, all play an important role in
treatment success [42, 72–75]. For example, working
alliance contributes to the success of CRT [72]; positive
mood facilitates creative problem solving [73]; intrinsic
motivation can be enhanced by providing a personalised
context that links treatment with everyday life, and also by
tailoring the intervention to the learning goals of each
participant [74, 75]; and functioning outcomes are best
achieved by combining CRT with other rehabilitation pro-
grammes [44].
Table 1 Principles guiding cognitive remediation intervention
Principle 1, Relationship Building: A major focus of each session is to prioritise the development of a strong therapeutic relationship. The therapeutic
relationship will be strengthened by providing a credible rational for participation, explicitly linking the cognitive remediation to patients’ goals, promoting
success experiences, making participation enjoyable, providing positive reinforcement, and managing ruptures, which may occur during the course of the
intervention.
Principle 2, Collaborative Goal Setting: So as to promote ‘buy in’ patients will be encouraged to develop a series of short term, medium term, and long
term goals. Patients neuropsychological and risk assessments e.g. HCR-20, Dundrum toolkit, will be shared with patients to create a platform to develop
goals. An explicit connection will also be drawn between cognitive difficulties and patients’ aspirations. Short term goals may include having the
concentration required to watch a TV programme or to read a book. Medium term goals may include patients’ ability to self-medicate or move to a less
secure unit. Long term goals may include returning to work, and developing relationships outside the hospital.
Principle 3, Session Structure: Each session will begin with a mood check to establish rapport or identify problems followed by agenda
setting, implementation of the agenda items, and summaries before moving on to the next agenda item. The session will end by giving
patients the opportunity to provide feedback.
Principle 4, Content of the sessions: The sequencing of interventions will be informed both by patients goals and their unique strengths
and vulnerabilities as documented by neuropsychological assessment. Cognitive domains at the start of the informational processing stream
e.g. attention and vigilance, working memory etc will typically be prioritised over those occurring later e.g. comprehension and social problem solving. This is
because difficulties associated with higher level cognitive processes may be a result of problems with more basic processes such as attention and memory.
As patients demonstrate some improvement in core cognitive skills, higher level domains will be targeted. Clinical judgement will be required to determine
if patients achieve a basic level of mastery in certain cognitive domains of if a ceiling has been reached before progressing to more complex domains. CRT
therapists should carefully assess whether patients are improving on core domains e.g. verbal memory etc., and if these improvements are being maintained
over time.
Principle 5, Pacing: Therapists are encouraged to avoid trying to squeeze too much into each session or to work on too many problems simultaneously
because it takes time to consolidate skills. In other words, patients need opportunities to repeat tasks again and again to improve performance, which is
referred to as massed practice. Throughout the intervention each session should build on the next and be targeted at concrete goals. Patients should be
provided with feedback on their progress towards goals. Newly acquired skills should not be abandoned once developed but refreshed during future
sessions. Patients may also need breaks between tasks. This down time is a good opportunity to ask patients about their lives and to strengthen the
therapeutic relationship.
Principle 6, Errorless Learning and Scaffolding: Task difficulty should be set so that patients obtain a high level of success on each task to avoid faulty
learning and to enhance morale. Patients will be required to obtain a success rate of 80 % before the cognitive demands of the task are increased. Where
problems are encountered therapists should provide scaffolding and model successful completion of tasks.
Principle 7, Meta cognitive Strategies: A major focus of each session will be to explicitly teach patients meta-cognitive strategies which are somewhat
independent of basic cognitive ability and can be flexibly applied across situations. Examples of meta-cognitive strategies include goal setting, visualisation,
focusing on one thing at a time, self-verbalisation, planning, breaking problems into parts, sequencing, chunking, advantage disadvantage analysis, perspective
taking, monitoring performance, reflecting on performance etc. It is particularly important to explicitly model the effective use of meta cognitive strategies for
patients. The effectiveness of strategies should be carefully assessed using a behavioural experiment framework. The use of particular strategies should be
consolidated as evidenced by generalisation before additional meta-cognitive strategies are introduced. When mastery of basic strategies has
been consolidated patients can be encouraged to simultaneously use multiple strategies.
Principle 8, Generalisation: Patients will be encouraged to utilise their cognitive skills outside of remediation sessions by participating in a support
group. The focus of the support group will be helping patients to develop a shared understanding of the cognitive deficits associated with schizophrenia,
to develop an awareness of how these deficits affect their lives, to identify situations where they can apply their cognitive skills, to obtain encouragement
and support from other members of the group on how to implement these skills, to strengthen narratives where success has been achieved. In addition
to the above positive group participation in and of itself may enhance cognitive processes as it requires patients to monitor their thoughts, reframe from
interruptions, structure their contributions, and reflect on feedback.
Principle 9, Managing Ambivalence: Patients ambivalence towards participating should be met in a non-defensive empathic manner. Advantages and
disadvantages of participating should be listed using pen and paper to ease the burden on working memory and to model effective problem solving.
Patents should be gently reminded of their goals and their initial commitment to participate for the duration of the intervention. Ways of making the
cognitive remediation more relevant or enjoyable should be actively explored.
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It is also hoped that the nine treatment principles will
form a bridge between abstract theoretical models and the
concrete interventions carried out during sessions. Our
approach combines models of cognitive remediation such
as drill and practice aiming to strengthen cognitive per-
formance as well as teaching meta-cognitive strategies
aiming to compensate for cognitive function, whilst at the
same time emphasising the process of therapy e.g. rela-
tionship building, goal setting, managing ambivalence etc.
In practical terms each session will involve practicing
discreet cognitive functions identified by the MATRICS
consensus cognitive battery [63] e.g. attention, working
memory, verbal memory, visual memory, comprehen-
sion, problem solving and social cognition. A variety of
pen and paper materials will be used to achieve this aim.
A free open source version of the Dual N-back com-
puter programme (http://brainworkshop.sourceforge.net)
will also be used to help patients develop and modulate
their attentional recourses in addition to their working
memory (visual and spatial) and processing speed. Over
the course of the intervention as patients make progress
the cognitive remediation procedures will gradually in-
crease in difficulty.
The cognitive remediation will be delivered by Masters’
level assistant psychologists and the cognitive remediation
support group will be delivered by multidisciplinary pro-
fessionals including psychiatric registrars, occupational
therapists and psychiatric nurses. All therapists contribut-
ing to the cognitive remediation programme will attend a
three day training course prior to delivering the interven-
tion. All therapists will attend weekly supervision sessions
where fidelity to the treatment principles will be actively
monitored. Fidelity to the treatment will also be assessed
by observing adherence to the nine treatment principles
during randomly selected individual and group treatment
sessions.
Treatment as usual
Participants in both conditions will receive treatment as
usual from hospital clinicians. At a minimum, this will
consist of antipsychotic pharmacotherapy and a thera-
peutically safe and secure environment appropriate to
the individual patient’s needs [76–78] however most pa-
tients are expected to be involved in a range of therapies
provided by multidisciplinary team members, including
psychiatrists, clinical psychologists, psychiatric nurses,
occupational therapists and social workers [78].
Medication will be managed separately by the consult-
ant psychiatrists responsible for the patients’ care and
may change over the duration of the study as required.
Both antipsychotic dose and anticholinergic burden will
be measured at each assessment point as these may be
important treatment moderators [79].
The number of routine therapeutic hours each patient re-
ceives in the treatment as usual (control) and the cognitive
remediation group will be recorded from patient’s progress
notes/ medical charts each week. A narrow definition of
therapeutic activity will be applied to prevent over inclu-
sion: a therapy will be defined as any activity that is occur-
ring on a consistent or regular basis targeting specific goals
and designed to address patients’ forensic mental health
needs. From this perspective regular occupational therapy,
cognitive behavioural work, psycho-education, harmful be-
haviour programmes, substance misuse interventions,
group programmes etc. would be defined as therapeutic ac-
tivities, in contrast multidisciplinary team meetings, general
interviews or assessments, physical exercise and general vo-
cational or educational work will not be seen as therapies.
Assessment battery
All assessors will complete a training programme prior
to administering study related assessments. For assess-
ments that require clinical judgment (e.g. symptom se-
verity measures), assessors will observe a number of
interviews carried out by an experienced consultant
psychiatrist whilst simultaneously rating patients' per-
formance. The inter-rater reliability of assessors will also
be measured as part of the training programme for as-
sessors. Primary and secondary outcome measures are
presented in Table 2.
Primary outcome measure: change in global cognitive
functioning
Cognitive functioning among study participants will be
assessed at baseline, end of treatment (approximately
6 months) and 8 month follow up using the MATRICS
Consensus Cognitive Battery (MCCB) global composite
score [61]. The MATRICS battery covers seven cognitive
domains: processing speed; attention/ vigilance; working
memory; verbal learning; visual learning; reasoning and
problem solving; social cognition assessed using social rea-
soning tasks for understanding and managing emotions
taken from the Managing emotions subtest of the Mayer-
Salovey-Caruso Emotional Intelligence Test (MSCEIT)
which is a social reasoning test. The test comprises of vi-
gnettes of various situations, and options for coping with
the emotions depicted in these vignettes [80, 81]. Partici-
pants are required to indicate the effectiveness of each so-
lution ranging from one (very ineffective) to five (very
effective). In validation studies, and in antipsychotic trials
of stable patients, the MATRICS demonstrated excellent
reliability, minimal practice effects and significant correla-
tions with measures of functional capacity. It is hypothe-
sised that there will be a group by time interaction (CRT
vs TAU) on the total score of the MATRICS battery at the
end of treatment approximately 6 months and at 8 months
follow up.
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Secondary outcome measures
Change in specific cognitive domains
The MATRICS battery will also be used to assess change
in specific cognitive domains for study participants. The
processing speed, attention/ vigilance, working memory,
visual learning, verbal learning, reasoning/ problem solv-
ing and social cognitive domains of the MATRICS bat-
tery will all be used as secondary outcome measures. It
is hypothesised that there will be a group (CRT vs TAU)
by time interaction on the MATRICS domain scores at
the end of treatment and eight month follow up [61]
Social cognitive measures
Changes in social cognition will be assed using The
Reading the Mind in the Eyes Test [62], the Faux Pas
Recognition Test [63] and the Managing Emotions sub-
test of the Mayer-Salovey-Caruso Emotional Intelligence
Test (MSCEIT). It is hoped that each of these tests will
tap into different components of the emotional process-
ing stream [40]. The Reading the Eyes of the Mind Test
will measure emotional perception as well as theory of
mind, the Faux Pas Recognition Test will measure the
participants awareness of emotional context or social
sensitivity, and finally the MSCEIT is a measure of social
as well as emotional reasoning.
Real world functioning
Secondary outcome measures will include the Social and
Occupational Functioning Assessment Scale (SOFAS)
[64]. The SOFAS is a continuous scale (0–100) with verbal
tethers so that higher scores represent superior function-
ing. It is similar to the Global Assessment of Functioning
Scale however it does not include the severity of psychi-
atric symptoms. Again it is hypothesised that there will be
a group (CRT vs TAU) by time interaction at the end of
treatment and eight month follow up.
Psychiatric symptoms
Secondary outcome measures will also include the scores
on the disorganised and negative symptoms scales from
the five factor Positive and Negative Syndrome Scale
(PANSS) and the total score from the Clinical Assessment
Interview for Negative Symptoms (CAINS) [67, 68]. The
PANSS contains 30 items measuring psychopathology as-
sociated with schizophrenia, 7 items assess positive symp-
toms, seven items assessing negative symptoms and 16
items assess general psychopathology. A five factor model
of the PANSS will be used to evaluate outcomes because
CRT is thought to have a specific impact on negative and
disorganised symptoms [82]. The CAINS is a 13 item
interview for measuring negative symptoms associated
with schizophrenia. It contains 9 items for assessing prob-
lems with motivation and pleasure and 4 items for asses-
sing problems with emotional expression. Again it is
hypothesised that there will be a group (CRT vs TAU) by
time interaction at the end of treatment and eight month
follow up.
Violence risk
Violence risk will be assessed with the Historical and
Clinical Risk Management Scale 20 (HCR-20) a measure
of violence risk, sometimes referred to as violence
proneness [51]. The HCR-20 is among the most widely
used violence risk assessment schemes. The HCR-20
contains ten historical or static items, five current or
clinical items and five future risk items. Both the clinical
and risk items are thought to be dynamic in nature in
that they can change over time and are amenable to
therapeutic intervention. Because the historical items are
static in nature only the dynamic items will be used as a
secondary outcome measurement. Violence risk will only
be measured at baseline and eight month follow up.
Again it is hypothesised that there will be a group (CRT
vs TAU) by time interaction. The HCR-20 will be rated
approximately every six months by the treating multi-
disciplinary team and researchers.
Programme completion and recovery
It is hoped that there will be differences between partici-
pants receiving CRT compared to TAU on their ability
to benefit from additional psychosocial treatment pro-
grammes offered. Participant ability to benefit from add-
itional psychosocial treatment will be assessed with the
Dundrum-3 Programme Completion scale rated by
Table 2 Outcome Measures
Primary Outcome
Measure






• The Reading the Mind in the Eyes Test
• The Faux Pas Recognition Test
• The MSCEIT
Social and Occupational Functioning Assessment
Scale (SOFAS)
Positive and Negative Syndrome Scale (PANSS) –
negative and disorganised scales
Clinical assessment interview for negative
symptoms (CAINS)
Historical Clinical Risk -20 (HCR-20)
DUNDRUM-3 Programme Completion Scale
DUNDRUM-4 Recovery Scale
Validity Checks Rate of enrolment, rate of retention, rate of




Service user developed interview.
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psychiatric registrars and by patients’ multidisciplinary
teams blind to the intervention [78]. The Dundrum-3 is
a structured clinical judgment instrument which assesses
whether patients have participated in, engaged and bene-
fited from psychosocial programmes and consists of
seven items: physical health, mental health, drugs and al-
cohol, problem behaviours, self-care and activities of
daily living, education occupation and creativity and
family and social networks. Each item is rated on a five
point scale with lower scores representing a higher level
of participation and engagement. Patient ability to re-
cover within a forensic setting will be assessed with the
Dundrum-4 Recovery Scales [78]. The Dundrum 4 con-
tains six items: stability, insight, therapeutic rapport,
leave, dynamic risk and victim sensitivity. Similar to the
DUNDRUM-3 Programme Completion Scale, each item
of the DUNDRUM-3 is also rated on a five point scale
with lower scores representing greater progress towards
recovery. The Dundrum-3 Programme Completion Scale
has been shown to significantly distinguish between
levels of security within a forensic setting and the
Dundrum-4 Recovery Scale has been shown to distin-
guish those given unaccompanied leave outside of a se-
cure forensic setting. Programme completion and
recovery will only be measured at baseline and eight
month follow up. Again it is hypothesised that there will
be a group (CRT vs TAU) by time interaction.
Patient satisfaction measure
An interview developed by service users will be used to
explore patient satisfaction with cognitive remediation
[45]. The interview will inquire about the following
areas: 1) task difficulty, 2) experience of sessions, 3) rela-
tionship with therapist and 4) impact of CRT on daily
life. The interview will be administered by a social
worker who will be independent of treatment and as-
sessment teams, to the intervention and to other assess-
ments. Patients will be reassured that their responses will
be anonymously recorded i.e. that their names will not be
connected with the feedback they provide.
Proposed analysis
Data analysis will be carried out using an intention to
treat methodology [83]. Data from all enrolled partici-
pants will therefore be used in the analysis regardless of
their level of participation in the study. Missing data will
be estimated using multiple imputation [84]
The interaction between time i.e. baseline vs. 6 month
and treatment condition (CRT vs TAU) on our primary
outcome variable (MCCB composite cognition score)
will be examined rather than between group differences,
because tests of group difference average Time 1 (base-
line) and Time 2 (6 month) assessments across the
groups and consequently will be less sensitive to change.
The interaction between time and treatment condition
will be assessed using a repeated measure ANOVA with
age and gender entered as covariates. This analysis will
also be repeated at follow up using all three data points.
An a priori estimate of statistical power was completed
using G*Power 3.1 [85]. Assuming a correlation greater
than or equal to .5 between baseline and 6 month
MCCB composite and a medium effect size (i.e. f = .25),
the power to detect a statistically significant interaction
between time and treatment conditions (i.e. CRT vs
TAU) is adequately powered i.e. greater than or equal to
.80. Should we find a statistically significant time X
treatment condition interaction, post-hoc probing of the
interaction will be completed with Bonferroni correc-
tions applied where appropriate to maintain an alpha of
0.05.
SPSS PROCESS Macro Model 4 will be used to ex-
plore mechanisms of action should we find a positive
impact of CRT. For example, whether change in cogni-
tion leads to a change in functioning, or whether a
change in negative symptoms leads to a change in func-
tioning etc. Change score will be calculated by subtract-
ing the scores at baseline from the sores following the
intervention. Age and gender will be entered as covari-
ates in all mediation analysis. Bootstrapping will be used
to estimate indirect effects, and 95 % bias-corrected con-
fidence intervals using 1,000 bootstrap samples will be
applied. A confidence interval that does not contain zero
indicates statistically significant mediation (p < 0.05).
Discussion
Forensic mental health services have a dual role in treat-
ing and caring for patients with mental disorders while
also protecting the public from recidivist acts of vio-
lence. This study aims to address both of these goals by
attempting to alleviate or ameliorate the likely common
underlying deficits leading to functional impairment and
violence.
Recently there has been a shift in emphasis within the
field of schizophrenia research from focusing on positive
symptoms such as delusions and hallucinations to pa-
tients’ cognitive abilities and functional outcomes [86].
Positive symptoms can be fairly successfully treated with
medication however to date there is a lack of effective
pharmacological treatments for cognitive difficulties and
negative symptoms [13, 14]. It is these difficulties which
are associated with patients’ ability to function day to
day [14]. Also many risk factors for violence for mentally
disordered patients concern suboptimal functioning.
CRT appears to be an effective intervention for com-
munity patients with schizophrenia for improving cogni-
tive deficits [42]. There is also evidence that the
cognitive improvements brought about by CRT lead to
improvements in patient functioning. Because forensic
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mental health patients tend to be hospitalised for a lon-
ger duration than those in the community there is an
unrealised opportunity to improve cognition and restore
functioning within forensic services [8].
The results of the proposed study will help to answer
the question whether cognitive remediation therapy is
an effective intervention strategy for forensic mental
health patients. Specifically it will test whether a nation-
ally representative cohort of forensic mental health pa-
tients with schizophrenia or schizoaffective disorder
benefit from cognitive remediation and whether patients
are satisfied with the intervention.
A focus on cognition as a primary treatment target also
has the potential to reduce violence risk in two ways. First
it could help patients who are cognitively impaired benefit
from specialised psychosocial programmes targeting the
risk of violence. Second it could improve general func-
tional ability. By placing the emphasis on cognition and
functional ability over symptoms any conflict between the
two roles played by forensic mental health services could
be reduced thus improving recovery and decreasing pa-
tients’ length of stay.
Limitations
The protocol has some limitations. A weakness of the
study is the lack of an active control group beyond treat-
ment as usual (TAU). An additional weakness is that it will
not be possible to keep medication constant for the dur-
ation of the study. The confined environment of a forensic
hospital may also present fewer opportunities for prac-
ticing and applying cognitive skills. In a non-quantitative
narrative review of over 100 psychological intervention
studies it was estimated that extra-therapeutic factors such
as the persons’ social environment accounted for approxi-
mately 40 % of the variance of the outcome of interven-
tions [87]. Forensic services almost by definition limit
patients’ freedom. And there can be conflict within forensic
mental health services between safety and security on the
one hand, and the provision of a therapeutic environment
on the other. However these disadvantages will be offset by
the consistency of the daily milieu for the intervention and
TAU groups, a consistency that cannot be achieved for
groups living in the community.
Strengths
A major strength of the study is that CRT is being of-
fered to a nationally representative cohort of forensic
mental health patients with schizophrenia or schizoaffec-
tive disorder. The findings regarding efficacy and patient
satisfaction will therefore inform whether CRT could or
should be rolled out in forensic mental health services
across other jurisdictions. A second strength of the study
is the large battery of outcome measures for assessing
the efficacy of the intervention, evaluating domains of
cognition, functioning, symptoms, programme comple-
tion, recovery and violence risk. Finally the patients
themselves will also play a role in assessing the useful-
ness of the intervention by participating in a confidential
interview.
Trial status
The trail is currently enrolling by invitation. Trial Regis-
tration: ClinicalTrials.gov Identifier: NCT02360813. First
received: February 4, 2015.
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